Latest Ratios: P/E Ratio -95.4x · EV/EBITDA N/A · ROE -8.7%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $20.0B | $19.2B | $10.4B | $13.3B | $8.7B | $13.3B | $20.0B | $12.1B | $7.7B | $6.1B | $1.4B |
| Enterprise Value | $21.6B | $20.7B | $12.5B | $15.3B | $10.9B | $15.4B | $20.9B | $12.9B | $8.2B | $6.0B | $1.3B |
| P/E Ratio → | -95.37 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.16 | 5.90 | 3.75 | 5.33 | 4.19 | 7.55 | 13.43 | 13.85 | 16.97 | 22.85 | 13.76 |
| P/B Ratio | 8.24 | 7.98 | 4.31 | 4.24 | 2.87 | 3.94 | 8.96 | 5.31 | 11.32 | 11.68 | 4.08 |
| P/FCF | 56.10 | 53.71 | 138.84 | 417.40 | — | — | 277.61 | — | — | — | — |
| P/OCF | 40.73 | 38.99 | 49.16 | 85.36 | — | — | 146.72 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.38 | 4.53 | 6.11 | 5.25 | 8.72 | 13.99 | 14.74 | 18.13 | 22.58 | 13.32 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 58.10 | 167.73 | 478.45 | — | — | 289.25 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.7% | 69.7% | 69.5% | 70.5% | 68.3% | 74.0% | 76.2% | 75.3% | 74.0% | 70.2% | 54.5% |
| Operating Margin | -6.4% | -6.4% | -38.0% | -8.6% | -28.5% | -48.4% | -51.5% | -26.7% | -35.1% | -44.5% | -170.1% |
| Net Profit Margin | -6.4% | -6.4% | -37.3% | -8.2% | -29.9% | -33.7% | -55.2% | -24.3% | -38.5% | -43.0% | -168.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.7% | -8.7% | -37.1% | -6.6% | -19.4% | -21.2% | -36.4% | -14.4% | -29.2% | -26.7% | -50.5% |
| ROA | -3.5% | -3.5% | -16.6% | -3.2% | -9.7% | -10.3% | -19.5% | -8.5% | -16.5% | -23.5% | -45.1% |
| ROIC | -3.6% | -3.6% | -16.3% | -3.1% | -8.3% | -15.0% | -18.8% | -8.2% | -14.4% | -24.0% | -43.4% |
| ROCE | -4.0% | -4.0% | -18.8% | -3.7% | -9.9% | -16.4% | -20.3% | -10.0% | -16.6% | -27.0% | -49.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.05 | 1.05 | 1.15 | 0.81 | 0.80 | 0.70 | 1.04 | 0.42 | 1.01 | 0.01 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.65 | 0.90 | 0.62 | 0.72 | 0.61 | 0.38 | 0.34 | 0.78 | -0.14 | -0.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 4.39 | 28.89 | 61.05 | — | — | 11.64 | — | — | — | — |
| Interest Coverage | — | — | -32.80 | -8.80 | -42.68 | -66.44 | -44.84 | -4.58 | -4.33 | -574.32 | -793.50 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.43 | 2.43 | 2.15 | 2.32 | 2.38 | 2.76 | 3.47 | 2.34 | 8.99 | 7.15 | 10.87 |
| Quick Ratio | 2.17 | 2.17 | 1.92 | 2.07 | 2.09 | 2.56 | 3.33 | 2.08 | 8.70 | 6.77 | 10.65 |
| Cash Ratio | 1.50 | 1.50 | 1.42 | 1.51 | 1.53 | 1.99 | 2.91 | 1.37 | 8.23 | 6.23 | 10.14 |
| Asset Turnover | — | 0.55 | 0.47 | 0.39 | 0.33 | 0.26 | 0.30 | 0.25 | 0.30 | 0.44 | 0.26 |
| Inventory Turnover | 5.92 | 5.92 | 5.17 | 5.79 | 5.59 | 4.37 | 3.84 | 3.51 | 3.01 | 3.04 | 6.61 |
| Days Sales Outstanding | — | 33.57 | 32.94 | 29.73 | 27.68 | 44.75 | 57.07 | 54.30 | 36.41 | 36.25 | 31.32 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.8% | 1.9% | 0.7% | 0.2% | — | — | 0.4% | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $189M | $184M | $180M | $176M | $171M | $151M | $131M | $122M | $116M | $102M |
Regulatory reimbursement and competition
Based on current market data, EXAS trades at a price-to-sales multiple of 6.16, which suggests investors are pricing in significant long-term market share gains despite the company's negative trailing twelve-month P/E ratio of -95.37 and persistent challenges in achieving consistent GAAP profitability.
The forward P/E of 582.83 indicates that the market is heavily discounting future earnings, placing the company in a high-growth category that is sensitive to any deviation from revenue targets. This valuation premium appears to rely on the assumption that the company will successfully transition from a high-burn expansion phase to a sustainable, high-margin diagnostic leader.
As reported in financial statements, the company's ROIC has hovered near negative territory, reaching -1.5% in 2025Q4, which indicates that the firm is currently failing to generate returns on invested capital that exceed its cost of capital, a trend that warrants further investigation by long-term investors.
The persistent negative ROIC suggests that the massive investments in laboratory infrastructure and commercial sales forces have not yet reached the critical mass required for efficient capital compounding. Until the company can demonstrate a sustained positive spread between its returns and its cost of capital, the current capital allocation strategy may continue to dilute shareholder value.
According to recent quarterly filings, the company's cash conversion cycle remains elevated, with days sales outstanding reaching 124 days in 2025Q4, reflecting the inherent complexities of navigating diverse insurance reimbursement networks and the associated delays in collecting payments for diagnostic services.
The high DSO relative to industry peers suggests that the company faces structural friction in its revenue collection process, which directly impacts its ability to convert top-line growth into immediate cash flow. Investors should monitor whether improvements in billing automation can compress this cycle, as current levels indicate significant capital is tied up in accounts receivable.
Based on the provided balance sheet data, the company maintains a debt-to-equity ratio of 1.05 as of 2025Q4, which indicates a reliance on external leverage that may limit the firm's strategic flexibility in a higher interest rate environment compared to more conservatively capitalized diagnostic peers.
The lack of consistent interest coverage, as evidenced by negative figures in several recent quarters, suggests that the company's debt service capacity is currently dependent on external financing rather than internal cash generation. This leverage profile increases the risk of equity dilution should the company need to refinance its obligations under less favorable market conditions.
The price-to-earnings ratio is frequently misapplied to this business model, as it fails to account for the heavy non-cash stock-based compensation expenses that obscure the underlying cash-generating potential of the company's core diagnostic screening and oncology testing operations.
Analysts should instead prioritize free cash flow margins and revenue-per-test metrics to better assess the firm's operational health. Relying on P/E ratios in a phase of aggressive commercial expansion ignores the significant investments being made to secure long-term market dominance, leading to a distorted view of the company's true economic value.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EXAS stock.
Exact Sciences Corporation's current P/E ratio is -95.4x. This places it at the 50th percentile of its historical range.
Exact Sciences Corporation's return on equity (ROE) is -8.7%. The historical average is -66.0%.
Based on historical data, Exact Sciences Corporation is trading at a P/E of -95.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Exact Sciences Corporation has 69.7% gross margin and -6.4% operating margin.